Arch co-leads $14M series A for Vizgen, which aims to overcome capacity limitations of single-cell RNA imaging tech. Co-founder David Walt is scientific founder of 2 other Arch portfolio cos: $ILMN & $QTRX via @LaboratoryLiz in @BioCenturyhttps://www.biocentury.com/biocentury/finance/2020-01-30/arch-thinks-vizgen%E2%80%99s-technology-could-improve-transcriptome-imaging- …
0 replies
1 proslijeđeni tweet
1 korisnik označava da mu se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.